Success Story: NIW Approval Without RFE for a Biomedical Science Expert from South Korea
Client’s Testimonial:
"Satisfied overall."
On May 19th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Ph.D. Student in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Ph.D. Student
Country of Origin: South Korea
State of Residence at the Time of Filing: Minnesota
Approval Notice Date: May 19th, 2026
Processing Time: 23 months, 2 days
Case Summary:
"His contributions have had a substantial impact on the nation’s response to the pandemic, demonstrating the important benefits of his research in public health."
The statement above is taken from one of four recommendation letters submitted as part of the EB-2 NIW (National Interest Waiver) petition for a holder of an M.S. in engineering, biomedical engineering from South Korea. Drawing on our extensive experience and a proven track record of over 32,000 successful cases, our expert team meticulously crafted a compelling petition on their behalf.
Client Background and Proposed Endeavor
As a Ph.D. student in the field of biomedical science, the client's proposed endeavor is to continue research on characterizing the mechanisms behind cardiovascular disease, cancer, and other age-related conditions to develop cutting-edge treatments in order to enhance patients' quality of life and reduce healthcare costs. Currently conducting this work at a leading U.S. research institution, the client is investigating the role of inflammatory signaling pathways in cardiac fibroblast reprogramming for the treatment of ischemic heart disease, as well as the use of specific inhibitors to limit angiogenesis in certain tumor types, research that sits at the intersection of regenerative medicine, oncology, and artificial intelligence.
National Significance of the Research
We emphasized that this research is of significant importance and has far-reaching implications for the United States. The client's work directly addresses critical national healthcare challenges by advancing the understanding of life-threatening diseases and age-related conditions that place a tremendous burden on patients, families, and the broader U.S. economy. By developing novel, mechanism-informed therapies, the research holds great promise for improving patient outcomes and reducing long-term healthcare costs nationwide. The work also aligns with federally identified critical and emerging technology areas, further reinforcing its national importance and the U.S. interest in the client's continued contributions.
Impressive Credentials and Achievements
To further strengthen the case, we highlighted exceptional credentials:
- Publications: An impressive portfolio of 4 peer-reviewed journal articles, 2 conference abstracts, and 1 patent application.
- Citations: The work has been cited 124 times.
- Competitive Funding: The research has been supported by an impressive range of major federal and international funding bodies, including the National Research Foundation (NRF) of Korea, the Korean Ministry of Science and ICT, the Center for Global Research Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Maryland Stem Cell Research Fund, the National Institutes of Health (NIH), the National Cancer Institute, the Rolfe Pancreatic Cancer Foundation, and the National Institute on Aging, affirming the broad significance and national importance of the work.
Case Outcome
Considering the exceptional strength of the accomplishments and the national importance of the proposed endeavor, we are delighted to share that this NIW petition was approved without RFE. The client's pioneering work in characterizing the mechanisms of cardiovascular disease, cancer, and age-related conditions, combined with demonstrated expertise spanning molecular virology, immunology, computational imaging, and aging biology, positions this researcher to make transformative contributions to U.S. public health and biomedical innovation for years to come.